Alpha Square Group S’s Rani Therapeutics RANI Stock Holding History

Alpha Square Group S’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-33,401	Closed	-$104K	–	23
2024 Q1	$104K	Sell	33,401 -25,545	-43%	-$87.8K	0.19%	20
2023 Q4	$196K	Sell	58,946 -28,000	-32%	-$64.7K	0.23%	20
2023 Q3	$189K	Sell	86,946 -14,627	-14%	-$55.9K	0.19%	20
2023 Q2	$418K	Hold	101,573	–	–	0.3%	14
2023 Q1	$524K	Sell	101,573 -30	-0%	-$180	0.28%	13
2022 Q4	$599K	Hold	101,603	–	–	0.26%	37
2022 Q3	$973K	Hold	101,603	–	–	0.44%	39
2022 Q2	$1.05M	Hold	101,603	–	–	0.44%	32
2022 Q1	$1.37M	Hold	101,603	–	–	0.19%	39
2021 Q4	$1.66M	Buy	+101,603	New	+$2.31M	0.34%	8

Other funds holding RANI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alpha Square Group S's RANI Position: Q2 2024 in Review

Alpha Square Group S sold out of Rani Therapeutics (RANI) in Q2 2024, closing a stake of 33,401 shares — an estimated $104K sold.

Alpha Square Group S first reported a position in RANI in Q4 2021 and held it in 10 quarters. The position peaked at $1.66M in Q4 2021. 34 funds tracked by Wall St. Rank hold RANI as of Q2 2024.

Alpha Square Group S reported no remaining Rani Therapeutics position as of Q2 2024 after selling out during the quarter.
Alpha Square Group S sold 33,401 Rani Therapeutics shares in Q2 2024, an estimated $104K.
Alpha Square Group S first reported a position in Rani Therapeutics in Q4 2021 and held it in 10 quarters.
Alpha Square Group S's Rani Therapeutics position peaked at $1.66M in Q4 2021.
34 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2024.

Based on Alpha Square Group S's 13F filing for Q2 2024, filed 15 Aug 2024.